Table 2.
Follow up and therapy modalities of patients with Mooren’s ulceration
| Case No. | Follow up time (month) | Numbers of AM- transplantation/Surgical procedures | Immunosuppressive therapy | Topical immunosuppressivetherapy | BCVA at initial visit | BCVA at last follow up | Epithelialisation (including conjunctivalisation) |
|---|---|---|---|---|---|---|---|
| 1 |
112 |
OD: 2x + KPL |
Cyclophosphamide (i.v.; ineffective) FK-506 |
Cyclosporin A AT 0.5% |
OD: < 20/4000 |
OD: <20/4000 |
2 month after AMT and effective immunosuppressive therapy |
| OS: 3x |
OS: 20/4000 |
OS: 20/4000 |
|||||
| 2 |
75 |
OD: 1x |
Cyclosporin A (orally) |
Cyclosporin A AT 0.5% |
OD: 20/2000 |
OD: 20/4000 |
3 month after AMT and effective immunosuppressive therapy |
| 3 |
14 |
OD: 4x |
Cylclophosphamide (i.v.) |
Cyclosporin A AT 0.5% |
OD: 20/80 |
OD: 20/2000 |
1 month after AMT and effective immunosuppressive therapy |
| 4 |
12 |
OD: 1x |
Cyclophosphamide (i.v.) |
Cyclosporin A AT 0.5% |
OD: 20/32 |
OD: 20/80 |
1 month after AMT and effective immunosuppressive therapy |
| 5 |
144 |
OD: 7x + conjunctival resection |
Cyclophosphamide (i.v.; ineffective) Cyclosporin A (orally; ineffective) Tacrolimus |
Cyclosporin A AT 0.5% |
OD: 20/32 |
OD: <20/4000 |
3 month after AMT and effective immunosuppressive therapy |
| OS: 20/20 |
OS: 20/32 |
||||||
| 6 |
232 |
OD: 4x + KPL enucleation |
Cyclophosphamide (i.v.) |
Cyclosporin A AT 0.5% |
OD: 20/25 |
OD: - |
3 month after KPL and effective immunosuppressive therapy |
| OS: 20/25 |
OS: 20/40 |
||||||
| 7 |
30 |
OD: 5x + conjunctival resection |
Cyclophosphamide (i.v.) Azathioprine |
Cyclosporin A AT 0.5% |
OD: 20/320 |
OD: 20/800 |
3 month after AMT and effective immunosuppressive therapy |
| OS: 3x + conjunctival resection | OS: 20/32 | OS: 20/63 |